Shen, Qiu-Dan <br/><br/>
Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.  [electronic resource] 

 -  The Lancet. Haematology  Jun 2018 
 - e261-e269 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>2352-3026 
<br/><br/><label>Standard No.: </label>10.1016/S2352-3026(18)30054-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antigens, CD20<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Rituximab--administration & dosage<br/>Treatment Outcome<br/>Gemcitabine